XTL Biopharmaceuticals (XTLB)

• Market cap: $9.54M
• 1 day: -5.41%
• 5 days: -4.37%
• 1 month: -16.27%
• 3 months: -38.60%
• 6 months: -32.69%
• Year to date: 79.05%
• 1 year: 75.02%
• 5 years: 33.59%
• 10 years: -85.71%

About: XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.

Employees: 4

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

0.03% less ownership

Funds ownership: 0.05% [Q2] → 0.02% (-0.03%) [Q3]

20% less capital invested

Capital invested by funds: $694K [Q2] → $556K (-$138K) [Q3]

25% less funds holding

Funds holding: 4 [Q2] → 3 (-1) [Q3]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1